Pharma BD Deal Intelligence
Pfizer snags U.S. rights to Cellectis' 'white-hot' UCART19 CAR-T via Servier sublicense — the first major Big Pharma validation of off-the-shelf allogeneic…
Positive framing of the collaboration's strategic value: it 'builds on Pfizer's position in the CAR-T space and our growing portfolio of investigational…
Phase 1 PALL/CALM trials of UCART19 showed 83% complete remission rate across adult and pediatric R/R B-ALL — first clinical proof-of-concept for an allogeneic…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Servier exercised its exclusive worldwide option from Cellectis for UCART19, an allogeneic CD19 CAR-T, and simultaneously sublicensed US rights to Pfizer. Cellectis received $38.2M at signing plus up to $300M+ in milestones plus royalties. Pfizer's allogeneic CAR-T portfolio later transferred to Allogene Therapeutics (2018); UCART19 program retained by Servier.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. and Les Laboratoires Servier / Cellectis SA (UCART19 program) (this deal) | 2015 | $338M | 22 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2015 deals · Hematology deals